Key result
Surgical epicardial EV-ICD lead placement is feasible, achieving successful sensing and defibrillation at 30 J.
Why the study?
Ebstein anomaly is a rare congenital heart disease often requiring invasive interventions to manage structural defects and associated supraventricular and ventricular arrhythmias.
Case Report (n=1)
This case demonstrates the feasibility of surgically implanting an EV-ICD lead on the epicardium in a patient with complex congenital heart disease and prosthetic tricuspid valve undergoing sternotomy, avoiding transvalvular leads.
Ebstein anomaly (EA) is a rare congenital heart disease characterized by apical displacement of the tricuspid valve and subsequent right ventricular failure. Invasive interventions are often needed to treat these structural defects and the associated supraventricular and ventricular arrythmias that commonly occur. We present a patient with EA who received a bioprosthetic tricuspid valve implant and the first reported surgical epicardial implantation of an extravascular implantable cardioverter-defibrillator (EV-ICD; Aurora EV-ICD, Medtronic, Minneapolis, MN) lead in the United States.
No takes yet. Share an insight, caveat, or question.
Deets et al. (2025) conducted a case report in Ebstein anomaly (n=1). Surgical epicardial implantation of an extravascular implantable cardioverter-defibrillator (EV-ICD) lead was evaluated on Successful implantation and defibrillation threshold testing. Surgical epicardial implantation of an extravascular implantable cardioverter-defibrillator lead was safely performed, achieving appropriate sensing and successful defibrillation at 30 J.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: